HTX-L01-008

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameHTX-L01-008

Drug Alias NameHTX-L01-008HTX-L01008

ClassificationCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > mRNABiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody +[4]

Mechanisms of ActionAnti-Glypican-3CD3 T-cell engagers

TargetsGlypican-3T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHopewell Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesHopewell Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A